For the treatment of liver fibrosis, connective tissue growth factor and its application chimeric vaccine

The present invention discloses a method for the treatment of liver fibrosis CTGF chimeric vaccine, the insertion of hepatitis B core antigen epitopes c / e1B cells by CTGF epitope, CTGF construct can be assembled into a chimeric hepatitis B core-like particle vaccine . The chimeric vaccine without adjuvant auxiliary, stimulate the body can still produce high titers of anti-CTGF neutralizing antibodies. The chimeric mice after vaccination, after liver fibrosis induced by carbon tetrachloride produced significantly reduced. By experimental verification, of CTGF chimeric vaccine of the present invention can inhibit the activation level in mouse liver hepatic stellate cells, but also can stimulate cell proliferation in liver, inhibition of hepatocyte apoptosis. In addition, the level of TGF-β1 after immunization of mice and PDGF also decreased significantly, which is highly conducive to slow the progression of liver fibrosis. The results showed that, CTGF vaccine can be successfully suppressed the chimeric liver fibrosis induced by carbon tetrachloride in mice. Therefore, CTGF chimeric vaccine is expected to be developed as an effective means of treatment of liver fibrosis.